Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Tax Provisions (2022 - 2025)

Amylyx Pharmaceuticals has reported Tax Provisions over the past 4 years, most recently at $46000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $46000.0 for Q4 2025, up 107.24% from a year ago — trailing twelve months through Dec 2025 was $46000.0 (up 111.7% YoY), and the annual figure for FY2025 was $46000.0, up 111.7%.
  • Tax Provisions for Q4 2025 was $46000.0 at Amylyx Pharmaceuticals, up from -$635000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for AMLX hit a ceiling of $1.9 million in Q2 2023 and a floor of -$2.1 million in Q4 2023.
  • Median Tax Provisions over the past 4 years was $100000.0 (2022), compared with a mean of $147181.8.
  • Peak annual rise in Tax Provisions hit 1618.0% in 2023, while the deepest fall reached 463.94% in 2023.
  • Amylyx Pharmaceuticals' Tax Provisions stood at $574000.0 in 2022, then tumbled by 463.94% to -$2.1 million in 2023, then soared by 69.6% to -$635000.0 in 2024, then skyrocketed by 107.24% to $46000.0 in 2025.
  • The last three reported values for Tax Provisions were $46000.0 (Q4 2025), -$635000.0 (Q4 2024), and $242000.0 (Q1 2024) per Business Quant data.